Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 835-842

  Layton, J Bradley ^a   Li, Dongmei ^b   Meier, Christoph R ^d   Sharpless, Julie L ^c   Stürmer, Til ^a   Jick, Susan S ^e   Brookhart, M Alan ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BASEL   (Switzerland)

^e BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; TESTOSTERONE DERIVATIVE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; COHORT ANALYSIS; DRUG USE; GENERAL PRACTITIONER; HEALTH INSURANCE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICARE; MEN'S HEALTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; UNITED KINGDOM; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG UTILIZATION REVIEW; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TESTOSTERONE; UNITED STATES; YOUNG ADULT;

EID: 84895832192     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3570     Document Type: Article

References (33)

1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in menwith androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
2. Travison TG, Araujo AB, Hall SA, McKinlay JB. Temporal trends in testosterone levels and treatment in older men. Curr Opin Endocrinol Diabetes Obes. 2009;16:211-217.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731. (Pubitemid 32207487)
4. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-598. (Pubitemid 34158223)
5. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93:2737-2745. (Pubitemid 352008544)
6. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241-4247. (Pubitemid 350074738)
7. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-769. (Pubitemid 43881152)
8. Iglesias P, Carrero JJ, Díez JJ. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol. 2012;25:31-42.
9. Liverman CT, Blazer DG, eds. Testosterone and Aging: Clinical Research Directions. Washington, DC: The National Academies Press; 2004.
10. Basaria S. Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale. Endocr Pract. 2013;19:853-863.
11. Delamothe T. Monkey business: reflections on testosterone. BMJ. 2012;345:e4967.
12. Gan EH, Pattman S, Pearce S, Quinton R. Many men are receiving unnecessary testosterone prescriptions. BMJ. 2012;345.
13. Hackett G, Kirby M, Jackson G, Wylie K. Evidence based medicine inevitably increases testosterone prescribing. BMJ. 2012;345.
14. Gorricho J, Gavilán E, Gérvas J. Marketing, not evidence based arguments, has probably increased testosterone prescribing. BMJ. 2012;345:e6905.
15. Gan EH, Pattman S, Pearce S, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf). 2013; 79:564-570.
16. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173:1465-1466.
17. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust. 2012;196:642-645.
18. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199:548-551.
19. Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009; 12:5-12.
20. Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med. 2006; 3:1085-1089. (Pubitemid 44644721)
21. McShane LM, Dorgan JF, Greenhut S, Damato JJ. Reliability and validity of serum sex hormone measurements. Cancer Epidemiol Biomarkers Prev. 1996;5:923-928. (Pubitemid 26382988)
22. Yun YM, Botelho JC, Chandler DW, et al. Performance criteria for testosterone measurements based on biological variation in adult males: recommendations from the Partnership for the Accurate Testing of Hormones. Clin Chem. 2012;58:1703-1710.
23. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369:1011-1022.
24. Jick H, Wilson A. The cost of prescription drugs: a comparison of two countries. Pharmacotherapy. 2012;32:967-969.
25. Jick H, Wilson A, Wiggins P, Chamberlain DP. Comparison of prescription drug costs in the United States and the United Kingdom, part 2: proton pump inhibitors. Pharmacotherapy. 2012;32:489-492.
26. Jick H, Wilson A, Wiggins P, Chamberlin DP. Comparison of prescription drug costs in the United States and the United Kingdom, part 3: methylphenidate. Pharmacotherapy. 2012;32:970-973.
27. Jick H, Wilson A, Wiggins P, Chamberlin DP. Comparison of prescription drug costs in the United States and the United Kingdom, Part 1: statins. Pharmacotherapy. 2012;32:1-6.
28. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
29. Basaria S, Davda MN, Travison TG, Ulloor J, Singh R, Bhasin S. Risk factors associated with cardiovascular events during testosterone administration in oldermenwith mobility limitation. J Gerontol A Biol Sci Med Sci. 2013;68:153-160.
30. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
31. XuL, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
32. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451-1457. (Pubitemid 41798454)
33. Collier CP, Morales A, Clark A, Lam M, Wynne-Edwards K, Black A. The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. J Urol. 2010;183:2294-2299.